Peptides for Erectile Dysfunction — Evidence Review
Erectile dysfunction has well-validated first-line therapy: PDE5 inhibitors (sildenafil, tadalafil, vardenafil). These are not peptides. The peptide angle for ED centers on the melanocortin system —…
Erectile dysfunction has well-validated first-line therapy: PDE5 inhibitors (sildenafil, tadalafil, vardenafil). These are not peptides. The peptide angle for ED centers on the melanocortin system — specifically PT-141 (bremelanotide) — which acts centrally rather than via peripheral vasodilation.
Peptides with FDA approval in adjacent indication
PT-141 (Bremelanotide / Vyleesi)
FDA-approved as Vyleesi for premenopausal hypoactive sexual desire disorder (HSDD) in women. Used off-label for erectile dysfunction in men.
Mechanism: melanocortin-4 receptor agonist with central action on sexual desire and arousal pathways. This is mechanistically distinct from PDE5 inhibitors — it works on the desire/initiation side rather than the mechanical side. Some men who don't respond to PDE5 inhibitors respond to PT-141, and vice versa.
Side effect profile is significant — nausea is the most common (~40% in trials), and PT-141 causes hypertensive episodes that can be problematic in cardiovascular disease. The FDA prescribing information lists CV disease as a contraindication. Skin hyperpigmentation can occur with frequent use.
Full PT-141 profile → | Bremelanotide overview →
Supporting cast
Kisspeptin
Hypothalamic peptide regulating GnRH and the HPG axis. Some research interest in male sexual function via testosterone-axis modulation. Clinical applications are still in research stages.
What the evidence does not support
- BPC-157, TB-500, or tissue-repair peptides for erectile function
- Growth-hormone secretagogues (CJC-1295, ipamorelin, MK-677) for ED — no published evidence supports this use
- PT-141 as a substitute for cardiovascular workup in ED — ED is often the first symptom of vascular disease and should trigger appropriate evaluation
- Use without addressing underlying causes (testosterone deficiency, vascular disease, depression, medication side effects)
Important safety considerations
- ED is frequently the earliest symptom of cardiovascular disease. New-onset ED warrants cardiovascular evaluation, not immediate peptide therapy.
- PT-141 contraindicated in significant cardiovascular disease (hypertensive episodes risk)
- Documented interactions with PDE5 inhibitors are limited but caution warranted; do not stack PT-141 with PDE5 inhibitors without clinical guidance
Where to source
- PT-141 vendor rankings — limited; PT-141 has fewer ranked vendors than the metabolic-peptide class
What we don't know
- Long-term safety of PT-141 in repeated use beyond clinical-trial timelines
- Whether kisspeptin will mature into a clinically useful ED therapy
- Optimal patient selection between PDE5 inhibitors and PT-141 (the desire-side vs mechanics-side question)
Methodology
Read the full methodology.
This page is educational. ED warrants medical evaluation including cardiovascular and endocrine assessment. PDE5 inhibitors remain first-line for most patients; PT-141 is a second-line option with a narrower safety window.